With cancer being one of the leading causes of death in the world, finding better treatments is an ever-present goal in the medical research space. One company, Sona Nanotech, is looking at the potential of nano-based cancer therapies to revolutionize cancer treatment. CEO of Sona Nanotech, Dr. Sonal Mahajan believes that cancer treatments fail because they lack specificity, sacrificing healthy, unaffected cells in their efforts to eradicate the cancerous cells. By utilizing the power of nanotechnology, the cancer cells can be targeted directly, leading to a more effective, less destructive treatment. Nano-based cancer therapies involve the use of specialized nanoparticles, that can be programmed to search and attach themselves to cancer cells, making them vulnerable to the treatment. In addition, Nano-based cancer therapies are much better than traditional treatments such as chemotherapy, radiation, and surgery. They can be used to not only treat the cancer but to prevent cancer from redeveloping, as well as reduce the side effects that traditional treatments come with. Sona Nanotech is striving towards making this medical breakthrough a reality, developing the first-ever gold nanorod based diagnostic and therapeutic ultrasound-targeted platform. They hope to get the breakthrough therapy ready for use in targeted cancer treatments as soon as possible. The future of Nano-based cancer treatments looks promising. After successfully demonstrating its potency in the animal models, the company looks to apply for the next stage of clinical trials. If all goes according to plan, the Nano-based cancer therapies could soon become standard in the medical world, revolutionizing the way that cancer is treated. The market potential for these treatments is huge, and Dr. Sonal Mahajan believes it is just a matter of time before these treatments are widely available. With a market estimated to be worth around $80 billion in 2020, it looks like Sona Nanotech is in a prime position to be one of the leading companies at the forefront of this medical revolution.